Description

4-[Butyl([2'-(1H-Tetrazol-5-Yl)[1,1'-Biphenyl]-4-Yl]Methyl)Amino]-5-Pyrimidinecarboxylic Acid is a high-purity, non-peptidic angiotensin II receptor antagonist intermediate, critical for the synthesis of advanced active pharmaceutical ingredients (APIs). Its complex molecular structure, featuring both tetrazole and pyrimidinecarboxylic acid moieties, makes it a key building block in modern cardiovascular drug development. This compound is essential for pharmaceutical R&D laboratories and manufacturers specializing in sartans and related therapeutic agents.

Application

• Pharmaceutical Intermediate: Primary use as a critical precursor in the synthesis of angiotensin II receptor blockers (ARBs) for hypertension and heart failure treatment.
• Active Pharmaceutical Ingredient (API) Development: Serves as a core structural component in the research and production of novel sartan-class APIs.
• Biochemical Research: Used in pharmacological studies to investigate the structure-activity relationship (SAR) of AT1 receptor antagonists.
• Process Chemistry & Scale-Up: Employed in optimizing synthetic routes and scaling production from laboratory to commercial batch sizes.
• Reference Standard: Acts as a high-purity analytical standard for quality control and regulatory compliance in API manufacturing.
• Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for custom synthesis projects.

Basic Information

Product Name	4-[Butyl([2'-(1H-Tetrazol-5-Yl)[1,1'-Biphenyl]-4-Yl]Methyl)Amino]-5-Pyrimidinecarboxylic Acid
CAS No.	141872-46-0
Molecular Formula	C27H27N9O2
Molecular Weight	509.57 g/mol
Synonyms	BIBR 277; BIBR-277; 4-[Butyl([2'-(1H-Tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl)amino]-5-pyrimidinecarboxylic acid; Telmisartan Intermediate; Telmisartan Impurity; 4-[Butyl([2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl)amino]pyrimidine-5-carboxylic acid; 5-[[4'-[2-Butyl-4-methyl-6-oxo-1,6-dihydro-5-pyrimidinyl]methyl][1,1'-biphenyl]-2-yl]-1H-tetrazole (related structure); ARB Intermediate
EINECS	Contact for details

Quality Control

Our production of this advanced pharmaceutical intermediate adheres to strict cGMP (current Good Manufacturing Practice) guidelines to ensure batch-to-batch consistency and traceability. Quality is verified through a comprehensive suite of analytical techniques including HPLC, NMR, and mass spectrometry. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting purity, identity, and impurity profiles to meet the stringent requirements of pharmaceutical development and regulatory submissions.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed in a dry environment to prevent moisture absorption. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.